Cargando…

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics

Dementia is a major problem of health in developed societies. Alzheimer's disease (AD), vascular dementia, and mixed dementia account for over 90% of the most prevalent forms of dementia. Both genetic and environmental factors are determinant for the phenotypic expression of dementia. AD is a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cacabelos, Ramón, Martínez, Rocío, Fernández-Novoa, Lucía, Carril, Juan C., Lombardi, Valter, Carrera, Iván, Corzo, Lola, Tellado, Iván, Leszek, Jerzy, McKay, Adam, Takeda, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312254/ https://www.ncbi.nlm.nih.gov/pubmed/22482072 http://dx.doi.org/10.1155/2012/518901

Ejemplares similares

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
por: Cacabelos, Ramón, et al.
Publicado: (2010)

Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Resting-State Network Disruption and APOE Genotype in Alzheimer's Disease: A lagged Functional Connectivity Study
por: Canuet, Leonides, et al.
Publicado: (2012)

Influence of Metabolic, Transporter, and Pathogenic Genes on Pharmacogenetics and DNA Methylation in Neurological Disorders
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2023)

Optimization of Antidepressant use with Pharmacogenetic Strategies
por: Torrellas, Clara, et al.
Publicado: (2017)

Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2018)

Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals
por: Corzo, Lola, et al.
Publicado: (2020)

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Personalized Management and Treatment of Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2022)

DNA Methylation in Neurodegenerative and Cerebrovascular Disorders
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2020)

Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice
por: Carrera, Iván, et al.
Publicado: (2012)

Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2022)

Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2023)

Cardiovascular and lipid-lowering effects of a marine lipoprotein extract in a high-fat diet-induced obesity mouse model
por: Carrera, Iván, et al.
Publicado: (2023)

Neuroprotective Effect of Nosustrophine in a 3xTg Mouse Model of Alzheimer’s Disease
por: Carrera, Iván, et al.
Publicado: (2023)

In vitro and in vivo cytotoxic effect of AntiGan against tumor cells
por: Lombardi, Valter R.M., et al.
Publicado: (2018)

In Vitro Screening for Cytotoxic Activity of Herbal Extracts
por: Lombardi, Valter R. M., et al.
Publicado: (2017)

Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
por: Cacabelos, Ramón, et al.
Publicado: (2019)

A Comparative Evaluation of a Novel Vaccine in APP/PS1 Mouse Models of Alzheimer's Disease
por: Carrera, Iván, et al.
Publicado: (2015)

Proteomic and Global DNA Methylation Modulation in Lipid Metabolism Disorders with a Marine-Derived Bioproduct
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2023)

Prevention of Chronic Experimental Colitis Induced by Dextran Sulphate Sodium (DSS) in Mice Treated with FR91
por: Lombardi, Valter R. M., et al.
Publicado: (2012)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
por: Carrera, Iván, et al.
Publicado: (2013)

Immunocytochemical Characterization of Alzheimer’s Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine
por: Carrera, Ivan, et al.
Publicado: (2014)

Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
por: Carrera, Iván, et al.
Publicado: (2019)

Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
por: Teijido, Óscar, et al.
Publicado: (2017)

DNA Methylation as a Biomarker for Monitoring Disease Outcome in Patients with Hypovitaminosis and Neurological Disorders
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2023)

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
por: Pierre-François, Marie Josette Déborah, et al.
Publicado: (2022)

Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
por: Carril, Juan C., et al.
Publicado: (2017)

AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2022)

Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer’s Disease
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2022)

Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2023)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
por: Zamani, M., et al.
Publicado: (2011)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
por: de la Torre, Rafael, et al.
Publicado: (2012)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
por: Stingl, Julia Carolin, et al.
Publicado: (2022)

Pharmacogenetics of Oral Antidiabetic Drugs
por: Becker, Matthijs L., et al.
Publicado: (2013)

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
por: Cacabelos, Ramon
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u37p4bde04ak281a5bdunvkr3a